YOUR SHORTLIST

Compare wearables

Compare up to 10 devices across categories. Keep the purpose and the source beside the numbers.

How price order works

Lowest recorded store prices take priority over announced or launch prices, within the selected source market. Currencies use the dated EUR reference rates. Deposits and recurring charges are excluded from price order; missing prices stay last. Original price records remain visible.

The differences that matter

Tandem Mobi

Prescription subcutaneous insulin delivery; regional Control-IQ+ eligibility applies.

Keep in mind US manufacturer pump indication: ages 2+. Control-IQ+ type 1 indication is ages 2+ and type 2 indication ages 18+; CGM age limits can be different.

Tandem t:slim X2

Prescription subcutaneous insulin delivery; regional Control-IQ+ eligibility applies.

Keep in mind US manufacturer pump indication: ages 2+. Control-IQ+ type 1 indication is ages 2+ and type 2 indication ages 18+; CGM age limits can be different.

Published specifications and documented constraints. See the full comparison below for prices and sources.

Scroll across the table to compare every model

Tandem Mobi versus Tandem t:slim X2
Biosensors & healthAdd a model
Tandem Mobi - Manufacturer photograph of Tandem Mobi.
Biosensors & health · Tandem Diabetes CareTandem MobiReleased
Tandem t:slim X2 - Manufacturer photograph of Tandem t:slim X2.
Biosensors & health · Tandem Diabetes CareTandem t:slim X2Released
Prices · all markets
Price not verified
0 offer records & sources

No verified price in this audit.

Price not verified
0 offer records & sources

No verified price in this audit.

Designed forPrescription subcutaneous insulin delivery; regional Control-IQ+ eligibility applies. ↗Prescription subcutaneous insulin delivery; regional Control-IQ+ eligibility applies. ↗
Form factorCompact wearable pump with infusion tubing ↗Touchscreen wearable insulin pump with infusion tubing ↗
Power & outputInductive charging ↗Rechargeable battery ↗
SoftwareNot verifiedIn-warranty software updates subject to eligibility/training ↗
Reservoir200 units ↗300 units ↗
ControlCompatible smartphone app and on-pump bolus button ↗Colour touchscreen; compatible mobile bolus option ↗
Ingress RatingIP28; tested eight feet for two hours ↗Not applicable to this category
CgmsDexcom G7 and G7 15 Day; exact age indications differ ↗Maker currently lists Dexcom G7 systems and FreeStyle Libre 3 Plus; configuration dependent ↗
MountingClip or optional adhesive sleeve ↗Not applicable to this category
AlgorithmControl-IQ+; predicts glucose 30 minutes ahead ↗Control-IQ+ ↗
ProfilesNot applicable to this categoryUp to six personal profiles with timed segments ↗
AvailabilityExact manufacturer model verified; market and purchase eligibility follow the linked manufacturer source.Exact manufacturer model verified; market and purchase eligibility follow the linked manufacturer source.
Important context
  • US manufacturer pump indication: ages 2+. Control-IQ+ type 1 indication is ages 2+ and type 2 indication ages 18+; CGM age limits can be different.
  • CGM sensors and infusion supplies are sold separately. The complete care configuration and clinical suitability are not independently assessed.
  • US manufacturer pump indication: ages 2+. Control-IQ+ type 1 indication is ages 2+ and type 2 indication ages 18+; CGM age limits can be different.
  • CGM sensors and infusion supplies are sold separately. The complete care configuration and clinical suitability are not independently assessed.
Editorial pick & releaseNo editorial ranking recordedNo editorial ranking recorded
EvidenceManufacturer source Checked 2026-10-12Manufacturer source Checked 2026-10-12

Battery claims use different conditions and are not a controlled benchmark. “Not verified” is an evidence gap, not a missing feature. Prices are dated regional snapshots. Deposits, bundles and historical launch prices are labelled. Brightness measurement methods and battery workloads vary by manufacturer.